In April 2026, Senti Biosciences announced a tax-free holding company reorganization designed to enhance corporate governance flexibility and operational scalability. Concurrently, its lead candidate SENTI-202 advances in Phase 1 clinical trials targeting relapsed/refractory AML, while a partnered program SN301A dosing was halted due to safety concerns. These developments mark crucial inflection points for Senti’s early-stage programmable cell therapy platform, influencing capital deployment, regulatory positioning, and partnership evolution amid lingering developmental, manufacturing, and financial risks.